奥沙利铂联合替吉奥新辅助化疗在胃癌根治术患者中的应用效果

Study on the Application Effect of Oxaliplatin Combined with Tegafur,Gimeracil and Oteracil Potassium as Neoadjuvant Chemotherapy in Patients with Radical Gastrectomy for Gastric Cancer

目的:探究奥沙利铂联合替吉奥新辅助化疗在胃癌根治术患者中的应用效果。方法:选取2020年1月-2021年1月福建省立医院胃肠外科收治的100例胃癌患者,根据随机数字表法将其分为对照组和观察组,每组50例。对照组采用替吉奥进行新辅助化疗后行手术治疗,观察组则采用奥沙利铂联合替吉奥新辅助化疗后行手术治疗。比较两组疗效、毒副反应发生率、血清血管内皮生长因子(VEGF)亚型(VEGF-A、VEGF-C及VEGF-D)及凋亡促进因子[B淋巴细胞瘤基因-2相关X蛋白(Bax)、半胱氨酸蛋白酶-3(Caspase-3)及线粒体促凋亡蛋白(Smac)]水平。结果:观察组总有效率高于对照组,差异有统计学意义(P<0.05)。两组血小板减少、腹泻、中性粒细胞减少及恶心呕吐发生率比较,差异均无统计学意义(P>0.05)。治疗前,两组VEGF-A、VEGF-C、VEGF-D、Bax、Caspase-3、Smac比较,差异均无统计学意义(P>0.05);治疗2、4个周期,观察组VEGF-A、VEGF-C及VEGF-D均低于对照组,Bax、Caspase-3、Smac均高于对照组,差异均有统计学意义(P<0.05)。结论:奥沙利铂联合替吉奥新辅助化疗在胃癌根治术患者中的应用效果较好,且可显著改善患者的VEGF亚型及凋亡促进因子的表达,因此在胃癌根治术患者中的应用价值相对较高。

Objective:To investigate the application effect of Oxaliplatin combined with Tegafur,Gimeracil and Oteracil Potassium as neoadjuvant chemotherapy in patients with radical gastrectomy for gastric cancer.Method:A total of 100 patients with radical gastrectomy for gastric cancer in Gastrointestinal Surgery of Fujian Provincial Hospital from January 2020 to January 2021 were selected,they were divided into control group and observation group according to the method of random number table,with 50 cases in each group.The control group were treated with Tegafur,Gimeracil and Oteracil Potassium,the observation group were treated with Oxaliplatin combined with Tegafur,Gimeracil and Oteracil Potassium.The efficacy,toxic and side effects rates,serum vascular endothelial growth factor(VEGF)subtypes(VEGF-A,VEGF-C and VEGF-D)and apoptosis promoting factors[B cell lymphoma/leukemia-2 associated X protein(Bax),cysteine-requiring aspartate protease(Caspase-3)and second mitochondria-derived activator of caspases(Smac)]were compared between the two groups.Result:The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).There were no significant differences in the incidences of thrombocytopenia,diarrhea,neutropenia,nausea and vomiting between the two groups(P>0.05).Before treatment,there were no statistically significant differences in VEGF-A,VEGF-C,VEGF-D,Bax,Caspase-3 and Smac between the two groups(P>0.05);after 2 and 4 cycles of treatment,the VEGF-A,VEGF-C,and VEGF-D of the observation group were lower than those of the control group,and the Bax,Caspase-3 and Smac of the observation group were higher than those of the control group,and the differences were statistically significant(P<0.05).Conclusion:The application effect of Oxaliplatin combined with Tegafur,Gimeracil and Oteracil Potassium as neoadjuvant chemotherapy in patients with radical gastrectomy for gastric cancer is better,and it can significantly improve the expression of VEGF subtypes and apoptosis promoting factors,so its application value in the patients with radical gastrectomy for gastric cancer is higher.